|
Dec 6
|
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
|
|
Dec 5
|
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
|
|
Dec 1
|
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
|
|
Oct 26
|
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Oct 26
|
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
|
|
Aug 8
|
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
|